145 related articles for article (PubMed ID: 36548096)
1. The Evolving Role of Radiation Therapy in DLBCL: From Early-Stage to Refractory Disease.
Jones G; Plastaras JP; Ng AK; Kelsey CR
Oncology (Williston Park); 2022 Dec; 36(12):718-727. PubMed ID: 36548096
[TBL] [Abstract][Full Text] [Related]
2. Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post-Autologous Stem Cell Transplant.
Ladbury C; Kambhampati S; Othman T; Hao C; Chen L; Wong J; Cao T; Herrera A; Mei M; Dandapani S
Int J Radiat Oncol Biol Phys; 2022 Jul; 113(3):594-601. PubMed ID: 35176414
[TBL] [Abstract][Full Text] [Related]
3. Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy.
Ababneh HS; Abramson JS; Johnson PC; Patel CG
Radiother Oncol; 2022 Oct; 175():65-72. PubMed ID: 35952976
[TBL] [Abstract][Full Text] [Related]
4. Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
Kaddu-Mulindwa D; Gödel P; Kutsch N; Heger JM; Scheid C; Borchmann P; Holtick U; Held G; Thurner L; Bewarder M; Rixecker T; Bittenbring JT
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e498-e506. PubMed ID: 35094950
[TBL] [Abstract][Full Text] [Related]
5. Long-term remissions in patients with early relapse of diffuse large B-cell lymphoma following high-dose chemotherapy, autologous stem cell transplantation, and radiotherapy of residual disease.
Metzner B; Welzel J; Müller TH; Casper J; Kimmich C; Petershofen EK; Renzelmann A; Rosien B; Thole R; Voss A; Willborn K; Köhne CH
Strahlenther Onkol; 2022 Jan; 198(1):39-46. PubMed ID: 34735577
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Transplant-Eligible Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Salvage Chemotherapy: The Gustave Roussy Experience.
Rassy E; Danu A; Ibrahim T; Lazarovici J; Ghez D; Michot JM; Arfi-Rouche J; Rossignol J; Vergé V; Dartigues P; Ribrag V
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e373-e380. PubMed ID: 33277224
[TBL] [Abstract][Full Text] [Related]
7. A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma.
Brooks TR; Caimi PF
Blood Rev; 2024 Jan; 63():101140. PubMed ID: 37949705
[TBL] [Abstract][Full Text] [Related]
8. Sequencing therapy in relapsed DLBCL.
Flowers CR; Odejide OO
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):146-154. PubMed ID: 36485076
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.
Bliven SP; Shea L; Bal S; Goyal G; Mehta A; Narkhede M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):825-834. PubMed ID: 35869021
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
[TBL] [Abstract][Full Text] [Related]
11. Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.
Ng AK; Yahalom J; Goda JS; Constine LS; Pinnix CC; Kelsey CR; Hoppe B; Oguchi M; Suh CO; Wirth A; Qi S; Davies A; Moskowitz CH; Laskar S; Li Y; Mauch PM; Specht L; Illidge T
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):652-669. PubMed ID: 29413279
[TBL] [Abstract][Full Text] [Related]
12. Impact of Radiation Therapy After High Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Lymphomas: A Single Center Experience.
Osmani AH; Khafaga Y; Rauf MS; Maghfoor I; Akhtar S
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e149-e160. PubMed ID: 34627735
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.
Harrysson S; Eloranta S; Ekberg S; Enblad G; El-Galaly TC; Sander B; Sonnevi K; Andersson PO; Jerkeman M; Smedby KE
Br J Haematol; 2022 Jul; 198(2):267-277. PubMed ID: 35468219
[TBL] [Abstract][Full Text] [Related]
14. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
Yang X; Min X; He W
Medicine (Baltimore); 2018 May; 97(21):e10845. PubMed ID: 29794780
[TBL] [Abstract][Full Text] [Related]
15. Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy.
Boyle J; Beaven AW; Diehl LF; Prosnitz LR; Kelsey CR
Oncology (Williston Park); 2014 Dec; 28(12):1074-81, 1084. PubMed ID: 25510806
[TBL] [Abstract][Full Text] [Related]
16. Advances in Immunotherapy for Diffuse Large B Cell Lymphoma.
Shouse G; Herrera AF
BioDrugs; 2021 Sep; 35(5):517-528. PubMed ID: 34264504
[TBL] [Abstract][Full Text] [Related]
17. Does Radiation Have a Role in Advanced Stage Hodgkin's or Non-Hodgkin Lymphoma?
Specht L
Curr Treat Options Oncol; 2016 Jan; 17(1):4. PubMed ID: 26739151
[TBL] [Abstract][Full Text] [Related]
18. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Doraiswamy A; Shah MR; Bannerji R
Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
[TBL] [Abstract][Full Text] [Related]
20. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
